Metabolic Regulation in Mitochondria and Drug Resistance

Yue Pan¹, Min Cao¹, Jianzhou Liu¹, Qing Yang¹, Xiaoyu Miao¹, Vay Liang W Go², Paul W N Lee³, Gary Guishan Xiao^{4

5

6

7}

Affiliations

¹ School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, China.
² Agi Hirshberg UCLA Center for Pancreas Diseases, University of California, Los Angeles, CA, USA.
³ Harbor University of California Los Angeles Medical Center, Torrance, CA, USA.
⁴ School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, China. gxiao@dlut.edu.cn.
⁵ Agi Hirshberg UCLA Center for Pancreas Diseases, University of California, Los Angeles, CA, USA. gxiao@dlut.edu.cn.
⁶ Harbor University of California Los Angeles Medical Center, Torrance, CA, USA. gxiao@dlut.edu.cn.
⁷ Functional Genomics and Proteomics Laboratories, Creighton University Medical Center, Omaha, NE, USA. gxiao@dlut.edu.cn.

PMID: 29178075
DOI: 10.1007/978-981-10-6674-0_11

Review

Metabolic Regulation in Mitochondria and Drug Resistance

Yue Pan et al. Adv Exp Med Biol. 2017.

. 2017:1038:149-171.

doi: 10.1007/978-981-10-6674-0_11.

Authors

Yue Pan¹, Min Cao¹, Jianzhou Liu¹, Qing Yang¹, Xiaoyu Miao¹, Vay Liang W Go², Paul W N Lee³, Gary Guishan Xiao^{4

5

6

7}

Affiliations

¹ School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, China.
² Agi Hirshberg UCLA Center for Pancreas Diseases, University of California, Los Angeles, CA, USA.
³ Harbor University of California Los Angeles Medical Center, Torrance, CA, USA.
⁴ School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, China. gxiao@dlut.edu.cn.
⁵ Agi Hirshberg UCLA Center for Pancreas Diseases, University of California, Los Angeles, CA, USA. gxiao@dlut.edu.cn.
⁶ Harbor University of California Los Angeles Medical Center, Torrance, CA, USA. gxiao@dlut.edu.cn.
⁷ Functional Genomics and Proteomics Laboratories, Creighton University Medical Center, Omaha, NE, USA. gxiao@dlut.edu.cn.

PMID: 29178075
DOI: 10.1007/978-981-10-6674-0_11

Abstract

Mitochondria are generally considered as a powerhouse in a cell where the majority of the cellular ATP and metabolite productions occur. Metabolic rewiring and reprogramming may be initiated and regulated by mitochondrial enzymes. The hypothesis that cellular metabolic rewiring and reprogramming processes may occur as cellular microenvironment is disturbed, resulting in alteration of cell phenotype, such as cancer cells resistant to therapeutics seems to be now acceptable. Cancer metabolic reprogramming regulated by mitochondrial enzymes is now one of the hallmarks of cancer. This chapter provides an overview of cancer metabolism and summarizes progress made in mitochondria-mediated metabolic regulation in cancer drug resistance.

Keywords: Drug resistance; Metabolism; Mitochondrial; Signaling pathway.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Metabolic Regulation in Mitochondria and Drug Resistance

Affiliations

Metabolic Regulation in Mitochondria and Drug Resistance

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources